Neeraj G. Patel
DownloadHi-Res Photo
About
Titles
Doctor of Medicine Candidate, Yale School of Medicine
Biography
Neeraj G. Patel is a third-year medical student at Yale School of Medicine, who graduated from Yale University with a B.A. in Molecular, Cellular, & Developmental Biology and Political Science (concentrating in Health Policy). Prior to medical school, he spent a year as a research assistant at the Program on Regulation, Therapeutics, and Law at Brigham & Women's Hospital and Harvard Medical School. His research interests focus on improving regulations concerning the approval, affordability, and marketing of medical products. He is also interested in health communication and journalism.
Education & Training
- BA
- Yale University, Molecular, Cellular, & Developmental Biology; Political Science
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Neeraj G. Patel's published research.
Publications Timeline
A big-picture view of Neeraj G. Patel's research output by year.
Reshma Ramachandran, MD, MPP, MHS
6Publications
Publications
2024
US FDA breakthrough therapy designation and consumer drug advertising: a recipe for confusion
Patel N, Mohammad A, Ross J, Ramachandran R. US FDA breakthrough therapy designation and consumer drug advertising: a recipe for confusion. The BMJ 2024, 384: e076138. PMID: 38383007, DOI: 10.1136/bmj-2023-076138.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and Concepts
2023
Trust and Regulation: Assuring Scientific Independence in the FDA's Emergency Use Authorization Process.
Patel NG, Kesselheim AS, Darrow JJ. Trust and Regulation: Assuring Scientific Independence in the FDA's Emergency Use Authorization Process. J Health Polit Policy Law 2023, 48: 799-820. PMID: 36995365, DOI: 10.1215/03616878-10637726.Peer-Reviewed Original ResearchTherapeutic Value of Drugs Frequently Marketed Using Direct-to-Consumer Television Advertising, 2015 to 2021.
Patel NG, Hwang TJ, Woloshin S, Kesselheim AS. Therapeutic Value of Drugs Frequently Marketed Using Direct-to-Consumer Television Advertising, 2015 to 2021. JAMA Netw Open 2023, 6: e2250991. PMID: 36637824, DOI: 10.1001/jamanetworkopen.2022.50991.Peer-Reviewed Original Research
2022
Using Multiple Authorized Generics to Maintain High Prices: The Example of Entacapone.
Rome BN, Egilman AC, Patel NG, Kesselheim AS. Using Multiple Authorized Generics to Maintain High Prices: The Example of Entacapone. Value Health 2022 PMID: 36266218, DOI: 10.1016/j.jval.2022.08.013.Peer-Reviewed Original ResearchThe $5 Billion Hop: Glatiramer Acetate and the US Patent System.
Patel NG, Kesselheim AS. The $5 Billion Hop: Glatiramer Acetate and the US Patent System. J Law Med Ethics 2022, 50: 852-856. PMID: 36883396, DOI: 10.1017/jme.2023.27.Commentaries, Editorials and Letters
2020
False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications.
Woloshin S, Patel N, Kesselheim AS. False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications. N Engl J Med 2020, 383: e38. PMID: 32502334, DOI: 10.1056/NEJMp2015897.Commentaries, Editorials and Letters